The Addition of Basiliximab to Cellcept, Neoral and Steroids Resulted in a Significant Reduction in Acute Renal Allograft Rejection.

Hartle, James E.; Bisordi, Joseph E.; Chao, Stan; Freeland, Michael J.; West, John C

doi:10.1097/00007890-200004271-00177

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The addition of basiliximab to a dual-therapy, cyclosporine-based immunosuppressive regimen has been shown to reduce the incidence of acute rejection in renal transplant recipients (6). More substantial reductions in the incidence of acute rejection have been achieved when basiliximab is used with cyclosporine-based triple therapy, including azathioprine or MMF (15)(16)(17). Basiliximab was well tolerated by patients in the present study.…”

Section: Discussionsupporting

confidence: 51%

Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 51%

Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Other studies have reported a lower incidence of DGF when an IL‐2R antagonist is included within a CsA‐based regimen (Table 1). A single‐center study of 55 consecutive renal transplant patients given CsA, MMF, and steroids with basiliximab has reported a significantly lower incidence of DGF, defined as need for post‐transplant dialysis, compared with a matched control group of 28 patients (22% vs. 43%, p = 0.05) (39). In a prospective multicenter study, 108 renal transplant patients were randomized to receive basiliximab or placebo, and initiated on CsA‐ME monotherapy with steroids added where clinically necessary (35).…”

Section: Il‐2r Antagonists: Reducing the Risk Of Dgf?mentioning

confidence: 99%

Use of IL‐2 receptor antagonists to reduce delayed graft function following renal transplantation: a review

Sandrini

2005

Clinical Transplantation

View full text Add to dashboard Cite

Delayed graft function (DGF) occurs in approximately 30% of renal transplant patients, and significantly increases risk of long-term graft loss. This article reviews the potential for use of interleukin-2 receptor (IL-2R) antagonists to reduce the burden of DGF. IL-2R antagonists decrease incidence of acute rejection without increasing risk of cytomegalovirus infection or malignancy, and show equivalent efficacy to lymphocyte-depleting antibody agents in standard risk patients with immediate graft function. The nephrotoxicity associated with calcineurin inhibitors (CNIs) has led to use of delayed or low-dose CNI regimens with induction therapy in patients with DGF. In this setting, use of an IL-2R antagonist with mycophenolate mofetil and steroids with delayed cyclosporine appears to be associated with a low incidence of biopsy-proven rejection and comparable renal function to patients with immediate function. Additionally, there is intriguing evidence to suggests that IL-2R antagonists may reduce risk of DGF occurring. A number of large-scale and smaller studies have reported a trend to reduced incidence of DGF or improved early renal function using IL-2R antagonists compared with placebo, although data are not entirely consistent. In conclusion, the ability of IL-2R antagonists to reduce acute rejection with no additional safety concerns makes them an attractive option for patients with DGF.

show abstract

A Multicenter, Prospective, Randomized, Double-Blind Trial of Basiliximab in Heart Transplantation

Mehra¹,

Zucker²,

Wagoner³

et al. 2005

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

The Addition of Basiliximab to Cellcept, Neoral and Steroids Resulted in a Significant Reduction in Acute Renal Allograft Rejection.

Cited by 5 publications

References 0 publications

Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial

Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial

Use of IL‐2 receptor antagonists to reduce delayed graft function following renal transplantation: a review

A Multicenter, Prospective, Randomized, Double-Blind Trial of Basiliximab in Heart Transplantation

Contact Info

Product

Resources

About